

Swedish Orphan Biovitrum Conference Call - Topline Results from Factor 9 Phase III Study

26 September 2012



Geoffrey McDonough
CEO


B-LONG: Registrational rFIXFc Study



Sequential PK[†]
 BeneFIX[®] rFIXFc (50 IU/kg)

Non-Sequential PK
 rFIXFc (50 IU/kg)

8 wk screening



[†] PK Subgroup dosed with BeneFIX[®] then crossover to rFIXFc